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Objective: The FMS-related tyrosine kinase 3 (FLT-3) gene is a hematopoietic growth factor receptor gene, an
independent negative prognostic factor, which affects the proliferation and differentiation of stem cells or
hematopoietic progenitor cells. Patients with FLT-3 gene mutations have a worse prognosis and respon-
siveness to chemotherapy than those without these mutations. Our study aims to establish a conventional
detection method for FLT3-ITD and D835 mutations in patients with acute myeloid leukemia (AML).
Materials and methods: In this study, we recruited 100 patients with AML. Primers were designed to
distinguish between wild-type FLT-3, FLT3-ITD, and D835 variants. Methods using a polymerase chain
reaction (PCR)-Agilent 2100 Bioanalyzer, PCR-ABI PRISM 3100 Genetic Analyzer, and PCReagarose gel
electrophoresis were compared.
Results: A high-accuracy, easily operated, low-cost technique to detect the FLT-3 variation with 99.9%
speciﬁcity was established in this study. The PCR platform, the Agilent 2100 Bioanalyzer (plus DNA 1000
LabChip kit) chip analysis platform, and the ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size
standard) short tandem repeat (STR) ﬂuorescence analysis platform were used in different experimental
comparisons. The ABI PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard) STR ﬂuorescence
analysis platformwas the most suitable method to detect FLT3 variants. This method has a high degree of
sensitivity, accuracy, and a speciﬁcity of 99.9%.
Conclusion: AML with the homozygous mutated FLT-3 may have a worse cure rate than AML with het-
erozygous mutation. This mutation is not related to drug resistance, but is a factor in a high risk of
relapse; it is also related to unfavorable overall survival. Our designed detection methods should provide
key information to develop personalized medicine for AML patients.
Copyright © 2015, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
In clinical and pathological terms, leukemia is subdivided into a
variety of groups. The ﬁrst division is between its acute andnetics, Center for Genetic
Section 3, Chung-Yang Road,
886 3 856 3092.
elief Tzu Chi Foundation. Publishechronic forms, and it can further be divided into nonlymphocytic
(i.e., bone marrow) and lymphoblastic leukemia according to the
source of leukemic cells [1]. Acute progression is extremely rapid
and survival is approximately 1e3months; in chronic progression,
patients can survive for 3e4 years even without treatment
(chronic myelogenous leukemia) or for > 5e10 years (chronic
lymphatic leukemia) [2e5]. Acute leukemia is most often caused
by premature hematopoietic stem cell proliferation, whereas
chronic leukemia occurs with abnormal mature hematopoietic
cells. Two kinds of chemotherapy are used in acute myeloidd by Elsevier Taiwan LLC. All rights reserved.
Table 1
PCR primers and probes labeled with dye for detecting FLT3-ITD and D835
mutations.a
D835 F-FAM CCGCCAGGAACGTGCTTG
R-HEX GCAGCCTCACATTGCCCC
F CCGCCAGGAACGTGCTTG
R GCAGCCTCACATTGCCCC
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with anthracycline and the traditional 3:7 therapy [6e9].
Remission-induction rates range from 60% to 85% and long-term
survival rates are approximately 20e40% for patients undergoing
consolidation and maintenance therapies after complete remis-
sion. Bone marrow transplantation and peripheral blood stem cell
transplantation have resulted in higher survival rates in younger
patients [10]. The cytogenetic study of leukemia is one of the
important prognostic indicators, which can show the unique
chromosomal rearrangement forms of AML that affect the
outcome. Other factors, including age, therapy-induced secondary
AML, a high white blood cell count, and genetic aberrations such
as mutation of FLT-3 and NPM1, etc. [11e14], carry different
prognostic impacts. The recurrence rate is a very important issue.
It has remained high after consolidation therapy, especially in
elderly patients. According to the Formosa Cancer Foundation, the
annual incidence of AML is approximately three to ﬁve/100,000 in
the population of Taiwan. This estimate suggests that 600e1000
people will contract leukemia every year, with an annual mortality
rate of about two to four/100,000 in the population. Disease sta-
tistics from 1979 to 2003 show that the overall annual incidence
rate of AML is approximately one/100,000 in the Taiwan popula-
tion [15]. In other areas, such as Nanjing, China, the overall average
annual incidence rate of leukemia was 3.68/100,000 from 2003 to
2007 [16]. In the United States, the annual incidence is approxi-
mately 3.4/10,000 and about 12,000 people suffer from leukemia
each year. Acute myelogenous leukemia has a high prevalence in
developed countries. From 2002 to 2003 in the United States, a
high mortality rate of about 2.7/10,000 was estimated after con-
ventional therapy for AML compared with an 80% mortality rate
after diagnosis [17e19].
The FMS-related tyrosine kinase 3 [FLT-3; also known as stem
cell tyrosine kinase 1 (STK1)] gene is a hematopoietic growth factor
receptor gene affecting the proliferation and differentiation of stem
cells or hematopoietic progenitor cells and is an independent
negative prognostic factor [20]. FLT-3 is overexpressed in the ma-
jority of AML cases in adult patients, and two FLT-3-speciﬁc variants
have been identiﬁed. Insertion of tandem duplication into exon 11
and exon 12 in the wild-type FLT-3 produces internal tandem
duplication (ITD), which results in constitutive activation of the
negative regulation of the juxtamembrane domain; repeated
lengths of the fragment contain 6e180 bases in the coding region
[21,22]. The ITD mutation leads to sustained spontaneous phos-
phorylation of the LT3 receptor and FLT-3 oncogene expression.
Activating the mutation of D835 within the activation loop of FLT-3
in human hematologic malignancies leads to persistent activation
of the FLT-3 receptor [23].
It is still controversial whether aggressive treatment is capable
of inﬂuencing the poor prognosis with these mutations. The FLT-3
mutation does not affect complete remission rates that indicate the
response to induction chemotherapy [24]. Our study aim was to
establish a polymerase chain reaction (PCR)-based system to detect
the FLT3-ITD and D835 mutations. Establishing the identiﬁcation of
these two variants from other subtypes of AML should provide
important genetic information and improve appropriate treatment.
In addition, we can also understand how these genetic markers
inﬂuence responses to chemotherapy.ITD 11F GCAATTTAGGTATGAAAGCCAGC
12R CTTTCAGCATTTTGACGGCAACC
12R-FAM CTTTCAGCATTTTGACGGCAACC
11F-HEX GCAATTTAGGTATGAAAGCCAGC
ATP ¼ ATP binding domain; F ¼ forward primer; JM ¼ juxtamembrane domain;
KID¼ kinase insert domain; Kinase 2¼ tyrosine-kinase domain 2; PCR¼ polymerase
chain reaction; R ¼ reverse primer; TM ¼ transmembrane domain.
a The internal tandem duplication (ITD) mutation is located at the JM domain. The
missense D835 is usually located in the TK2.2. Materials and methods
2.1. Study patients
We recruited 100 AML patients at Wan Fang Hospital, Taipei,
Taiwan. Informed consent was obtained from all participants. Allprocedures were approved by the Institutional Review Board at
Wan Fang Hospital.2.2. PCR primers
To test the gene patterns of FLT3-ITD mutations and D835,
primers designed to distinguish between the wild-type FLT-3 gene
and the mutant FLT3-ITD gene, and between the D835 mutants
were distinguished by restriction enzyme digestion after PCR, as
shown in Table 1. In a previous study, an FLT3wild-type fragment of
approximately 329 bp was ampliﬁed using genomic DNA as a
template in PCR; in addition, an FLT3 fragment of 456 bp was
ampliﬁed using reverse transcription-PCR [21]. The size of the ITD
fragments ranged from 6 bp to 180 bp. The FLT3-ITD demonstrated
different lengths of DNA fragments compared with the wild type.2.3. PCR
The PCR conditions in this study were as follows: at 95C for 12
minutes, 95C for 30 seconds, 50C for 45 seconds, and 72C for 1
minute for 40 cycles, followed by 72C for 10 minutes, and then
stopped at 4C.2.4. Restriction enzyme digestion
The D835 mutant type showed around 113 bp and the wild type
could be digested by restriction enzyme at around 64 bp. Advanced
EcoRV digestion was carried out at 37C for 1 hour and 30 minutes,
and then stopped at 4C. The resulting short DNA fragments could
be identiﬁed range from 20 bp to 200 bp.2.5. The Agilent 2100 Bioanalyzer (plus DNA 1000 LabChip kit)
The Agilent 2100 Bioanalyzer plus DNA 1000 LabChip kit (Agi-
lent Technologies, Santa Clara, CA, USA) was used for the analysis of
DNA and RNA. The resulting DNA fragments (25 bpe1 kb) ranged
from 5 bp to 100 bp.
Table 2
Comparison of FLT mutation detection methods developed in this study.
Method Sizing resolution Samples
per run
Run
time
Dye Calling Price (NT)
per sample
Equipment
cost
2% Agarose electrophoresis 20e200 bp 1e24 2 ha No Eye vision 1.6 (24 samples)b Very low
Agilent 2100 bioanalyzer
(plus DNA 1000 LabChip kit)
10% gel (from 25 -100 bp)
5% gel (from100 -500 bp)
2% gel ( from 500 -1000 bp)
1e12 30 mina A dye concentrate
is mixed with the gel
Analyzer software 79 (12 samples)c Medium
ABI PRISM 3100 Genetic Analyzer
(plus GeneScan-500 size standard)
1e500 bp 1e16 1.5 ha Fluorescein-labeled
primer
Analyzer software 200 (16 samples)d High
a Estimation of time required is less than or equal to the maximum number of samples.
b Estimation of the price for a single sample batch of 24 samples.
c Estimation of the price for a single sample batch of 12 samples.
d Estimation of the price for a single sample batch of 16 samples.
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standard)
The PCR-ABI PRISM 3100 Genetic Analyzer [Applied Biosystems
(ABI), Forest City, CA, USA] was used for DNA analysis. In this
method, we used a blue ﬂuorescent tag (carboxyﬂuorescein) in the
inverted primer (reverse primer) as shown in Table 2 and capillary
electrophoresis. The resulting DNA fragments (35e500 bp) ranged
from 1 bp to 500 bp [24].
3. Results
3.1. Concentration and sensitivity tests for ITD and D835 primers
using PCReagarose electrophoresis
The series dilution of DNA for PCR demonstrated the limitations
of the ITD/D835 primers. The DNA concentration limitationwas 5 fg
and the primer dimer was demonstrated to be low DNA-
concentration dependent (Fig. 1). The DNA sample was mixed in
different ratios of the ITD wild type (RS4-11; 100 ng) to the mutant
form (MV4-11; 25 ng) or RS4-11(25 ng) with MV4-11(100 ng) for
PCR. Only a high concentration of DNA was detected (data not
showed) in the series dilution of the DNA concentration.
3.2. Concentration and sensitivity test for ITD primer using the
Agilent 2100 Bioanalyzer (plus DNA 1000 LabChip kit)
The results were the same as the PCR results, and the primer
dimer was also demonstrated to be low DNA-concentration
dependent (data not shown). The DNA ratio test showed the
same results as the PCR. In the DNA ratio of the mutant form (25 ngM  1   2   3   4   5   6   7   8   9  
Fig. 1. Testing for sensitivity and detection limitations of the internal tandem duplication (IT
50 fg, and 5 fg); 10e18 ¼ D835 100 bp (100 ng, 50 ng, 5 ng, 500 pg, 50 pg, 5 pg, 500 fg, 50
indicates 113 bp. The open arrowhead indicates primer dimers.or 2.5 ng) with the ITD wild type (100 ng) and the ratio of the ITD
wild type (2.5 ng) with the mutant form (100 ng), the DNA frag-
ment was detected only in high concentrations in the series dilu-
tion of the DNA concentration (Fig. 2). The DNA concentration
limitation was 5 fg (data not shown).
3.3. Concentration and sensitivity test for ITD primer using the ABI
PRISM 3100 Genetic Analyzer (plus GeneScan-500 size standard)
short tandem repeat
In the concentration tests, the ITD wild type and mutant form
were detected in a ratio of wild type (2.5 ng) with the mutant form
(2.5 ng). The obtained result was the same as that obtained earlier
using the PCReagarose electrophoresis and the Agilent 2100 Bio-
analyzer. Only high concentrations of DNA could be detected in the
series dilution ratio. In the sensitivity test for the ITD and D835
primers, short tandem repeat (STR) analysis could detect 5 fg of the
DNA concentration (Fig. 3).
3.4. Technical analysis and comparison
In Table 2, the three techniques are compared, and the detection
limitations and the required running times for each method are
presented. The minimal resolutions of detection were from 5 bp to
20 bp and the running times ranged from 30 minutes to 2 hours.
3.5. The FLT3-ITD and D835 mutation frequencies in AML
In our cohort, we showed the genotype/allele frequency in pa-
tients: the heterozygous variation occurred in 7.7% and homozy-
gous variation in 1.1% of patients with FLT3-ITD; the heterozygous10  11  12  13  14  15  16  17  18 
D) and D835 primers. 1e9 ¼ ITD 330 bp (100 ng, 50 ng, 5 ng, 500 pg, 50 pg, 5 pg, 500 fg,
fg, and 5 fg); M ¼ 100-bp marker. The arrow indicates 330 bp. The closed arrowhead
Fig. 2. The concentration ratio test of the internal tandem duplication wild type and mutant form. Samples 1e4 ¼ RS4-11, 100 ng/various concentrations of MV4-11 (100 ng, 50 ng,
25 ng, and 2.5 ng); Samples 5e8 ¼ MV4-11, 100 ng/various concentrations of RS4-11 (100 ng, 50 ng, 25 ng, and 2.5 ng). The arrows indicate 330 bp and > 330 bp.
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D835 heterozygous variation in 1% of AML patients (Fig. 4, Table 3).
The number of base pairs in AML patients was < 335 bp for the
wild-type allele, and ranged from 350 bp to > 475 bp for themutantFig. 3. Different types of internal tandem duplication (ITD) fragmentsallele in FLT3-ITD patients. The average number of base pairs for
FLT3-ITD was 328.73 bp and the average fragment length of D835
was around 63.64 bp for the wild-type allele. Most patients had the
heterologous allele; the homologous allelewas detected in only oneon short tandem repeat analysis. AML ¼ acute myeloid leukemia.
Fig. 4. The percentage of FLT-3 internal tandem duplication (ITD) and D835 genotypes in acute myeloid leukemia (AML) patients. DM ¼ double mutant allele;
Hetero ¼ heterozygous allele; WT ¼ wild-type allele.
Table 3
Genotypes of FLT-ITD and D835 in the enrolled AML patients.
ID ITD Genotype D835 Genotype
1 NA NA NA NA
2 329.01 WT 63.61 WT
3 328.82 WT 63.66 WT
4 328.82 WT 63.7 WT
5 329.05 WT 63.62 WT
6 328.86/482.49 Heterozygous 63.69 WT
7 328.78 WT 63.65 WT
8 328.99 WT 63.64 WT
9 328.51 WT 63.48 WT
10 328.87 WT 63.74 WT
11 328.9/416.52 Heterozygous 63.63 WT
12 348.94 Homozygous 63.64 WT
13 NA NA NA NA
14 328.78 WT 63.77 WT
15 NA NA NA NA
16 NA NA NA NA
17 328.75 WT 63.73 WT
18 328.77 WT 63.74 WT
19 328.74 WT 63.75 WT
20 328.85 WT 63.63/111.84 Heterozygous
21 328.72 WT 63.66 WT
22 NA NA NA NA
23 328.84 WT 63.68 WT
24 329.01 WT 63.64 WT
25 328.52/351.47 Heterozygous 63.68 WT
26 328.58/374.71 Heterozygous 63.7 WT
27 328.54 WT 63.66 WT
28 328.56 WT 63.72 WT
29 328.56 WT 63.66 WT
30 328.53/380.69 Heterozygous 63.57 WT
31 328.51 WT 63.69 WT
32 328.6 WT 63.7 WT
33 NA NA NA NA
34 328.94 WT 63.57 WT
35 328.32 WT 63.45 WT
36 329.18 WT 63.64 WT
37 329.07 WT 63.58 WT
38 328.54 WT 63.74 WT
39 328.53 WT 63.67 WT
40 328.52 WT 63.68 WT
41 329 WT 63.64 WT
42 328.56 WT 63.71 WT
43 328.55 WT 63.66 WT
44 328.65 WT 63.67 WT
45 328.56 WT 63.69 WT
46 329.02 WT 63.52 WT
47 328.41 WT 63.45 WT
48 NA NA NA NA
Table 3 (continued )
ID ITD Genotype D835 Genotype
49 NA NA NA NA
50 329 WT 63.62 WT
51 328.38 WT 63.67 WT
52 328.38 WT 63.74 WT
53 328.35 WT 63.75 WT
54 328.39 WT 63.74 WT
55 328.44 WT 63.7 WT
56 NA NA NA NA
57 328.46 WT 63.76 WT
58 328.39 WT 63.76 WT
59 328.42 WT 63.42 WT
60 328.51 WT 63.39 WT
61 328.44 WT 63.76 WT
62 328.39 WT 63.74 WT
63 328.43 WT 63.75 WT
64 329.05 WT 63.58 WT
65 328.4 WT 63.65 WT
66 329.05 WT 63.62 WT
67 328.44 WT 63.65 WT
68 329.01 WT 63.67 WT
69 328.5 WT 63.66 WT
70 328.54 WT 63.63 WT
71 329.09 WT 63.65 WT
72 329.18 WT 63.51 WT
73 329.26 WT 63.62 WT
74 328.88 WT 63.61 WT
75 329.18/392.59 Heterozygous 63.63 WT
76 329.22/380.56 Heterozygous 63.69/111.89 Heterozygous
96 328.84 WT 63.63 WT
99 328.99 WT 63.62 WT
100 329.87 WT 62.63 WT
AML ¼ acute myeloid leukemia; ITD ¼ internal tandem duplication; NA ¼ not
applicable; WT ¼ wild type.
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348.94-bp mutant genotype.
4. Discussion
The overall frequency of FLT3 mutation was 17.5% [25] and the
frequency of FLT3-ITD in the adult group of patients was 18.8%,
whichwas lower than in other ethnic populations, such as Germans
(32% and 21%, respectively) [26e28] and Japanese (23% and 31%,
respectively) [29]. One report summed up previous data and
showed an approximate rate of 17.7% [30]. Another report found an
incidence of 24% in elderly ( 60 years) patients and 22.8% in young
H.E. Liu et al. / Tzu Chi Medical Journal 27 (2015) 18e24 23patients. The report also mentioned that these mutations could
have a prognostic impact in elderly patients [31]. Some previous
studies concluded that it is possible DNA banks were used, which
likely overestimated the real incidence of FLT3-ITDmutations in the
population [32,33]. A previous study also agreed that the frequency
of FLT3-ITD is higher (18.8%) in adults compared with young AML
patients [34]. In the Taiwanese population, a previous study found
that the frequency of FLT3-ITD was 15.4% (14/91 pediatric patients)
[35]. Other studies reported that FLT3-ITD occurred in 12.6% of AML
patients in Taiwan [36e38]. In this study, the FLT3-ITD mutation
was detected in 8% (8/100) of adults in Taiwan and the D835 mu-
tation was detected in 2% of adults (1 patient had both mutations).
The frequencies of the FLT3-ITD and D835 mutation were lower in
our study than in previous studies in AML patients in Asian pop-
ulations [35e38]. Because our sample size was small, the results
only reﬂect the status of the patients recruited and do not present
the real frequency of the FLT3 mutation in Taiwan. The data
demonstrated risk variations in patients with ITDmutations of over
330-bp and D835 mutations of around 110-bp fragments in the
Taiwan population. AML patients with the homozygous mutated
FLT-3may have a worse cure rate than those with the heterozygous
mutation. This mutation is not related to drug resistance, but rather
is a factor in a high risk of relapse; it is also related to unfavorable
overall survival (OS). Some small molecular drugs use FLT3-ITD as
the test marker. Some treatment regimens have greater efﬁcacy in
this poor-risk subset of patients with AML. The STR platform
analysis to detect FLT3-ITD could analyze mutant differences in
many cases, aiding prediction of outcomes and the development of
possible novel therapies [39]. Disease-free survival (DFS) is also
worse for patients with FLT3-ITD than those with the wild type. It is
still not clear whether patients with D835 mutations have a worse
OS and DFS compared with those with the wild type [40e42].
Identiﬁcation of additional targets is needed to improve therapy.
We established three detection methods for FLT3-ITD and D835
in AML patients and compared their sensitivity and speciﬁcity in
this study. A technique to detect FLT-3 variationwith high accuracy,
easy operation, and low cost was developed. A comparison of the
three methods showed that the ABI PRISM 3100 Genetic Analyzer
(plus GeneScan-500 size standard) fragment analysis platform had
a higher sensitivity and resolution than the PCR electrophoresis
analysis platform and the Agilent 2100 Bioanalyzer (plus DNA 1000
LabChip kit) chip analysis platform for 16 samples processed at the
same time. According to the 100 cases provided by Wan Fang
Hospital for validation, the results demonstrated high accuracy and
99.9% speciﬁcity. The results should provide a high-quality diag-
nostic assay for personalized medicine for AML patients.
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